Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)	Cerebral Small Vessel Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Urogenital Diseases, Xerostomia, acquired idiopathic inflammatory myopathy, anti-neutrophil cytoplasmic antibody-associated vasculitis, arthritic joint disease, arthropathy, autoimmune disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, connective tissue disorder, dry eye syndrome, eye disorder, glomerulonephritis, granulomatosis with polyangiitis, immune system disorder, interstitial lung disease, kidney disorder, lacrimal apparatus disorder, lung disorder, lupus nephritis, microscopic polyangiitis, mouth disorder, muscle tissue disorder, musculoskeletal system disorder, myositis disease, necrotizing vasculitis, nephritis, nervous system disorder, neuromuscular disease, respiratory system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, skin disorder, skin vascular disease, systemic lupus erythematosus, systemic sclerosis, urinary system disorder, vascular disorder, vasculitis	Recruiting	Phase 1 / Phase 2	2024-10-15		NCT06350110

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Essen Biotech	17

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
District One Hospital	Beijing	China	17